An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib (NCT05887609)
A Phase II Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine-gynx and Olaparib in Recurrent Platinum Sensitive Ovarian, Peritoneal, and Fallopian Tube Cancer
🩺 Plain-English Summary (8th-Grade Level)
The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.
Who can join: Review the eligibility criteria below.
Location: City of Hope Lennar — Irvine, California
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- City of Hope Lennar — Irvine, California
- University of Colorado Hospital — Aurora, Colorado
- Northwestern Memorial Hospital — Chicago, Illinois
- University of Pennsylvania Health System, Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
- UPMC Magee-Women's Hospital — Pittsburgh, Pennsylvania
- University of Wisconsin - Carbone Cancer Center - University Hospital — Madison, Wisconsin
📞 Contact the Study Coordinator
Phone: (303) 724-2435
Email: kailey.palmen@cuanschutz.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ovary Cancer
- Dysregulation of Whole-body Metabolism in Ovarian Cancer: A Longitudinal Study — Knoxville, Tennessee
- Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment) — Chicago, Illinois
- Multimedia Aid for Genetic Testing in Gynecologic Oncology — Chapel Hill, North Carolina
- Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer — Baltimore, Maryland
- Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy — Chicago, Illinois
Explore by condition: All Ovary Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.